| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5616599 | COSETTE | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
Apr, 2016
(8 years ago) | |
|
US5616599 (Pediatric) | COSETTE | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
Oct, 2016
(7 years ago) | |
| US6878703 | COSETTE | Pharmaceutical composition |
Nov, 2021
(2 years ago) | |
|
US6878703 (Pediatric) | COSETTE | Pharmaceutical composition |
May, 2022
(1 year, 11 months ago) | |
Benicar Hct is owned by Cosette.
Benicar Hct contains Hydrochlorothiazide; Olmesartan Medoxomil.
Benicar Hct has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Benicar Hct are:
- US5616599
- US5616599*PED
- US6878703
- US6878703*PED
Benicar Hct was authorised for market use on 05 June, 2003.
Benicar Hct is available in tablet;oral dosage forms.
Benicar Hct can be used as use as an antihypertensive agent, treatment of hypertension.
The generics of Benicar Hct are possible to be released after 19 May, 2022.
Drugs and Companies using HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL ingredient
Market Authorisation Date: 05 June, 2003
Treatment: Use as an antihypertensive agent; Treatment of hypertension
Dosage: TABLET;ORAL
BENICAR HCT family patents
